Alzamend Neuro, Inc. Common Stock

Go to Alzamend Neuro, Inc. Common Stock Website

$2.59

0.27 (11.64%)
Live
Previous Close

$2.38

Day Range

$2.3012 - $2.39

Previous Day Range

$2.2 - $2.37

Market Cap

$6.7 million USD

Day Vol.

111279

Previous Day Vol.

149714

Currency

USD

Primary Exchange

Nasdaq

Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market...


Community
  • 0 posts discussing
0

Watchers

0

Visitors


Recent News

The Dow Jones index closed lower by around 0.1% on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. Aldeyra Therapeutics The Trade: Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) 10% owner Joseph Edelman acquired a total of 504,272 shares an average price of $3.84. To acquire these shares, it cost around $1.93 million. What’s Happening: On April ...

Related tickers: RVP, ALDX, ALZN.

Read Full Article

The Dow Jones index closed lower by over 200 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. Alzamend Neuro The Trade: Alzamend Neuro, Inc. (NASDAQ: ALZN) Director Milton C Ault III acquired a total of 2,000 shares an average price of $1.06. To acquire these shares, it cost around $2,127.. What’s Happening: On Dec. 11, 2023, Alzamend Neuro received a "Study May Proceed" letter from the FDA for the initiation of study AL001-PTSD01, a Phase 2A study of AL001 for post-traumatic stress disorder (PTSD). What ...

Related tickers: AZTR, SILO, GANX, ALZN.

Read Full Article
Trending Tickers

Please sign in to view